A study of JPI-547 with bevacizumab for recurrent ovarian cancer maintenance
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new combination of two drugs (JPI-547 and bevacizumab) as maintenance therapy after platinum-based chemotherapy and a PARP inhibitor. It's for people with recurrent ovarian, fallopian tube, or primary peritoneal cancer who have a BRCA mutation or HRD deficiency.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have recurrent ovarian, fallopian tube, or primary peritoneal cancer that is high-grade serous or certain endometrioid types.
- You have a known BRCA gene mutation or homologous recombination deficiency (HRD).
- You received platinum-based chemotherapy, followed by a PARP inhibitor as maintenance, and your cancer responded to the platinum therapy.
- You are able to take care of yourself (ECOG score 0 or 1).
- Your blood counts, kidney, and liver function are within normal limits (confirmed by lab tests).
- You are not pregnant or breastfeeding, and you agree to use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two PARP inhibitors (drugs that help repair DNA damage) combined with bevacizumab (an anti-angiogenic therapy) as maintenance treatment after chemotherapy in patients with advanced ovarian cancer that has a genetic vulnerability called HRD-positive. The goal is to see which combination works better at preventing cancer recurrence.
This trial tests whether a maintenance treatment with fluzoparib (a PARP inhibitor) plus bevacizumab can help keep advanced ovarian cancer from coming back in people who do not have a BRCA gene mutation and whose cancer responded to initial chemotherapy.
This trial tests a new combination therapy (SYS6041 plus another drug) for women with recurrent ovarian cancer. It is for those whose cancer has come back after platinum chemotherapy, and who have not had too many previous treatments. The goal is to see if the combination can shrink tumors or slow disease progression.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
This trial tests adding trastuzumab to standard maintenance therapy with bevacizumab for patients with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if the combination helps keep the cancer from growing longer.
This trial tests whether a combination of medications (hydroxychloroquine, everolimus, and others) can help keep ovarian cancer from coming back after successful platinum chemotherapy plus Avastin. It is for people whose cancer responded well to their most recent chemo and who can continue Avastin maintenance.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.